Aktis OncologyAKTS -5.49%9 Quick Ratio is 19.49 as of Mar. 2026, which is 21% above its 10-year median of 16.07. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Aktis Oncology ranks better than 91.88% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Aktis Oncology's quick ratio for the quarter that ended in Mar. 2026 was 19.49.
Aktis Oncology has a quick ratio of 19.49. It generally indicates good short-term financial strength.
The historical rank and industry rank for Aktis Oncology's Quick Ratio or its related term are showing as below:
AKTS'
s Quick Ratio Range Over the Past 10 Years
Min: 7.37 Med: 16.07 Max: 25.11
Current: 19.49
During the past 4 years, Aktis Oncology's highest Quick Ratio was 25.11. The lowest was 7.37. And the median was 16.07.
AKTS's Quick Ratio is ranked better than 91.88% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs AKTS: 19.49
Aktis Oncology (NAS:AKTS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Aktis Oncology Quick Ratio Related Terms
Aktis Oncology Quick Ratio Historical Data
* Premium members only.
The historical data trend for Aktis Oncology's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aktis Oncology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aktis Oncology Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aktis Oncology's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Aktis Oncology's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Aktis Oncology's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aktis Oncology (AKTS) has a Quick Ratio of 19.49 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aktis Oncology and its competitors. This is 21% above median its historical median of 16.07. Over the past decade, Aktis Oncology's Quick Ratio has ranged from 7.37 to 25.11. According to the industry distribution chart, Aktis Oncology ranks #115 out of 1416 companies in the Biotechnology industry, placing it in the top 8.1%.
Is Aktis Oncology's Quick Ratio too high?
Aktis Oncology's current Quick Ratio of 19.49 is 21% above median its 10-year median of 16.07. Over the past 10 years, this metric has ranged from a low of 7.37 to a high of 25.11. The Biotechnology industry median Quick Ratio is 3.60. Aktis Oncology's value of 19.49 is 441.4% above this industry median. Based on the distribution chart, Aktis Oncology ranks #115 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Quick Ratio compare to OLMA and EYPT?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #115 out of 1416 companies for Quick Ratio. This places Aktis Oncology in the top 8% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Aktis Oncology's value of 19.49 is 441.4% above this benchmark. Historically, Aktis Oncology's own Quick Ratio has ranged from 7.37 to 25.11 over the past decade. While the company's 10-year median is 16.07 vs. the industry median of 3.60, Aktis Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aktis Oncology's current Quick Ratio of 19.49 is 441.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aktis Oncology and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aktis Oncology's current Quick Ratio is 19.49, which is 21% above median its own 10-year median of 16.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Quick Ratio of 19.49. The current Quick Ratio is 19.49, which is 21% above median its 10-year median of 16.07 and 441.4% above the Biotechnology industry median of 3.60. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Quick Ratio is 19.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score
Get the complete analysis for AKTS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTS has been successfully added to your 